Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.

Tourrel C, Bailbé D, Meile MJ, Kergoat M, Portha B

Diabetes1 Jul 2001Cited by 260 (Europe PMC)

PMID11423477DOI10.2337/diabetes.50.7.1562PepBankPUB-11423477

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In n0-STZ rats, exendin‑4 increased body weight on day 7.
In plain wordsIn rats, exendin‑4 increased body weight compared with untreated rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBody weight on day 7
Study
ratn: not reported in source
neonatal streptozotocin-treated Wistar rats
Comparator
untreated n0-STZ rats
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · postnatal day 2 to day 6As given in this study (rat).
Source sentences
Summary
On day 7, both treatments increased body weight, decreased basal plasma glucose, decreased insulinemia, and increased pancreatic insulin content in n0-STZ rats.
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, n0-STZ rats were submitted to GLP-1 or exendin-4 from postnatal day 2 to day 6 only, and their beta-cell mass and pancreatic functions were tested on day 7 and at 2 months.
Report a problemFND-1142347701
02AnimalAnimal study (in vivo)Efficacy outcome
In n0-STZ rats, exendin‑4 decreased basal plasma glucose on day 7.
In plain wordsIn rats, exendin‑4 reduced basal blood glucose compared with untreated rats.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBasal plasma glucose on day 7
Study
ratn: not reported in source
neonatal streptozotocin-treated Wistar rats
Comparator
untreated n0-STZ rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · postnatal day 2 to day 6As given in this study (rat).
Source sentences
Summary
On day 7, both treatments increased body weight, decreased basal plasma glucose, decreased insulinemia, and increased pancreatic insulin content in n0-STZ rats.
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, n0-STZ rats were submitted to GLP-1 or exendin-4 from postnatal day 2 to day 6 only, and their beta-cell mass and pancreatic functions were tested on day 7 and at 2 months.
Report a problemFND-1142347702
03AnimalAnimal study (in vivo)Efficacy outcome
In n0-STZ rats, exendin‑4 decreased insulinemia on day 7.
In plain wordsIn rats, exendin‑4 reduced blood insulin compared with untreated rats.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInsulinemia on day 7
Study
ratn: not reported in source
neonatal streptozotocin-treated Wistar rats
Comparator
untreated n0-STZ rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · postnatal day 2 to day 6As given in this study (rat).
Source sentences
Summary
On day 7, both treatments increased body weight, decreased basal plasma glucose, decreased insulinemia, and increased pancreatic insulin content in n0-STZ rats.
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, n0-STZ rats were submitted to GLP-1 or exendin-4 from postnatal day 2 to day 6 only, and their beta-cell mass and pancreatic functions were tested on day 7 and at 2 months.
Report a problemFND-1142347703
04AnimalAnimal study (in vivo)Efficacy outcome
In n0-STZ rats, exendin‑4 increased pancreatic insulin content on day 7.
In plain wordsIn rats, exendin‑4 increased pancreatic insulin compared with untreated rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePancreatic insulin content on day 7
Study
ratn: not reported in source
neonatal streptozotocin-treated Wistar rats
Comparator
untreated n0-STZ rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · postnatal day 2 to day 6As given in this study (rat).
Source sentences
Summary
On day 7, both treatments increased body weight, decreased basal plasma glucose, decreased insulinemia, and increased pancreatic insulin content in n0-STZ rats.
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, n0-STZ rats were submitted to GLP-1 or exendin-4 from postnatal day 2 to day 6 only, and their beta-cell mass and pancreatic functions were tested on day 7 and at 2 months.
Report a problemFND-1142347704
05AnimalAnimal study (in vivo)Efficacy outcome
In n0-STZ rats, exendin‑4 increased beta-cell mass to 71% of the Wistar control value.
In plain wordsIn rats, exendin‑4 increased beta-cell mass compared with untreated diabetic rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBeta-cell mass on day 7
Study
ratn: not reported in source
neonatal streptozotocin-treated Wistar rats
Comparator
untreated n0-STZ rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · postnatal day 2 to day 6As given in this study (rat).
Measurements
Beta-cell mass
71%
Wistar control value
Source sentences
Summary
At the same age, the beta-cell mass, measured by immunocytochemistry and morphometry methods, was strongly increased in n0-STZ/GLP-1 and n0-STZ/Ex rats compared with n0-STZ rats, representing 51 and 71%, respectively, of the beta-cell mass in Wistar rats, whereas n0-STZ beta-cell mass represented on…
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, n0-STZ rats were submitted to GLP-1 or exendin-4 from postnatal day 2 to day 6 only, and their beta-cell mass and pancreatic functions were tested on day 7 and at 2 months.
Report a problemFND-1142347705
06AnimalAnimal study (in vivo)Efficacy outcome
In n0-STZ rats, the early improvement in beta-cell mass after exendin‑4 persisted at adult age.
In plain wordsIn rats, early exendin‑4 maintained higher beta-cell mass into adulthood compared with untreated diabetic rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBeta-cell mass at adult age
Study
ratn: not reported in source
neonatal streptozotocin-treated Wistar rats
Comparator
untreated n0-STZ rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · postnatal day 2 to day 6As given in this study (rat).
Source sentences
Summary
Despite such early improved beta-cell mass, which is maintained at adult age, the basal and glucose-stimulated insulin secretion (in vivo after intravenous glucose load or in vitro using perfused pancreas) were not improved in the 2-month-old n0-STZ rats previously treated with GLP-1 or exendin-4 co…
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, n0-STZ rats were submitted to GLP-1 or exendin-4 from postnatal day 2 to day 6 only, and their beta-cell mass and pancreatic functions were tested on day 7 and at 2 months.
Report a problemFND-1142347706
07AnimalAnimal study (in vivo)Efficacy outcome
In adult n0-STZ rats, neonatal exendin‑4 did not improve basal insulin secretion in vivo versus untreated rats.
In plain wordsIn rats, early exendin‑4 did not improve basal insulin release compared with untreated rats.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBasal insulin secretion in vivo at 2 months
Study
ratn: not reported in source
neonatal streptozotocin-treated Wistar rats
Comparator
untreated n0-STZ rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · postnatal day 2 to day 6As given in this study (rat).
Source sentences
Summary
Despite such early improved beta-cell mass, which is maintained at adult age, the basal and glucose-stimulated insulin secretion (in vivo after intravenous glucose load or in vitro using perfused pancreas) were not improved in the 2-month-old n0-STZ rats previously treated with GLP-1 or exendin-4 co…
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, n0-STZ rats were submitted to GLP-1 or exendin-4 from postnatal day 2 to day 6 only, and their beta-cell mass and pancreatic functions were tested on day 7 and at 2 months.
Report a problemFND-1142347707
08AnimalAnimal study (in vivo)Efficacy outcome
In adult n0-STZ rats, neonatal exendin‑4 did not improve glucose-stimulated insulin secretion in vivo versus untreated rats.
In plain wordsIn rats, early exendin‑4 did not improve glucose-stimulated insulin release compared with untreated rats.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeGlucose-stimulated insulin secretion in vivo at 2 months
Study
ratn: not reported in source
neonatal streptozotocin-treated Wistar rats
Comparator
untreated n0-STZ rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · postnatal day 2 to day 6As given in this study (rat).
Source sentences
Summary
Despite such early improved beta-cell mass, which is maintained at adult age, the basal and glucose-stimulated insulin secretion (in vivo after intravenous glucose load or in vitro using perfused pancreas) were not improved in the 2-month-old n0-STZ rats previously treated with GLP-1 or exendin-4 co…
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, n0-STZ rats were submitted to GLP-1 or exendin-4 from postnatal day 2 to day 6 only, and their beta-cell mass and pancreatic functions were tested on day 7 and at 2 months.
Report a problemFND-1142347708
09AnimalAnimal study (in vivo)Efficacy outcome
In adult n0-STZ rats, neonatal exendin‑4 reduced basal plasma glucose versus untreated rats.
In plain wordsIn rats, early exendin‑4 reduced adult blood glucose compared with untreated rats.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBasal plasma glucose at adult age
Study
ratn: not reported in source
neonatal streptozotocin-treated Wistar rats
Comparator
untreated n0-STZ rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · postnatal day 2 to day 6As given in this study (rat).
Source sentences
Summary
However, both treated groups significantly exhibited a decreased basal plasma glucose level and an increased plasma glucose clearance rate compared with the 2-month-old untreated n0-STZ group at adult age.
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, n0-STZ rats were submitted to GLP-1 or exendin-4 from postnatal day 2 to day 6 only, and their beta-cell mass and pancreatic functions were tested on day 7 and at 2 months.
Report a problemFND-1142347711
10AnimalAnimal study (in vivo)Efficacy outcome
In adult n0-STZ rats, neonatal exendin‑4 increased plasma glucose clearance versus untreated rats.
In plain wordsIn rats, early exendin‑4 increased adult blood glucose clearance compared with untreated rats.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePlasma glucose clearance at adult age
Study
ratn: not reported in source
neonatal streptozotocin-treated Wistar rats
Comparator
untreated n0-STZ rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · postnatal day 2 to day 6As given in this study (rat).
Source sentences
Summary
However, both treated groups significantly exhibited a decreased basal plasma glucose level and an increased plasma glucose clearance rate compared with the 2-month-old untreated n0-STZ group at adult age.
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, n0-STZ rats were submitted to GLP-1 or exendin-4 from postnatal day 2 to day 6 only, and their beta-cell mass and pancreatic functions were tested on day 7 and at 2 months.
Report a problemFND-1142347712
11LabEx vivo tissueEfficacy outcome
In perfused pancreata from adult n0-STZ rats, neonatal exendin‑4 did not improve basal insulin secretion versus untreated rats.
In plain wordsIn lab tests, pancreata from exendin‑4-treated rats did not release more basal insulin than untreated rat pancreata.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBasal insulin secretion in perfused pancreas
Study
ratn: not reported in source
perfused pancreata from adult rats treated neonatally with streptozotocin
Comparator
untreated n0-STZ rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · postnatal day 2 to day 6As given in this study (rat).
Source sentences
Summary
Despite such early improved beta-cell mass, which is maintained at adult age, the basal and glucose-stimulated insulin secretion (in vivo after intravenous glucose load or in vitro using perfused pancreas) were not improved in the 2-month-old n0-STZ rats previously treated with GLP-1 or exendin-4 co…
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, n0-STZ rats were submitted to GLP-1 or exendin-4 from postnatal day 2 to day 6 only, and their beta-cell mass and pancreatic functions were tested on day 7 and at 2 months.
Report a problemFND-1142347709
12LabEx vivo tissueEfficacy outcome
In perfused pancreata from adult n0-STZ rats, neonatal exendin‑4 did not improve glucose-stimulated insulin secretion versus untreated rats.
In plain wordsIn lab tests, pancreata from exendin‑4-treated rats did not release more glucose-stimulated insulin than untreated rat pancreata.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeGlucose-stimulated insulin secretion in perfused pancreas
Study
ratn: not reported in source
perfused pancreata from adult rats treated neonatally with streptozotocin
Comparator
untreated n0-STZ rats
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · postnatal day 2 to day 6As given in this study (rat).
Source sentences
Summary
Despite such early improved beta-cell mass, which is maintained at adult age, the basal and glucose-stimulated insulin secretion (in vivo after intravenous glucose load or in vitro using perfused pancreas) were not improved in the 2-month-old n0-STZ rats previously treated with GLP-1 or exendin-4 co…
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, n0-STZ rats were submitted to GLP-1 or exendin-4 from postnatal day 2 to day 6 only, and their beta-cell mass and pancreatic functions were tested on day 7 and at 2 months.
Report a problemFND-1142347710

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.